Research Comparison
Adipotide (Prohibitin-TP01) vs Cagrilintide (AM833)
A side-by-side research comparison of Adipotide (Prohibitin-TP01) and Cagrilintide (AM833) drawn from Cobalt Peptides' peptide database records.
Adipotide (Prohibitin-TP01)
Adipotide (Prohibitin-TP01) is a chimeric peptidomimetic combining a targeting sequence (CKGGRAKDC) that binds prohibitin and annexin A2 on adipose endothelial cells with a pro-apoptotic mitochondrial-disrupting motif, D-(KLAKLAK)2. It was investigated in preclinical models of adiposity. Its development was HALTED following early clinical investigation because of renal safety findings — reversible proximal tubule toxicity observed in primate studies. It is not an approved medicine and is supplied strictly as a research compound for laboratory use.
Cagrilintide (AM833)
Cagrilintide (AM833) is a long-acting, lipidated amylin analogue with activity at both amylin and calcitonin receptors. Its acylation gives an extended half-life suited to once-weekly administration in study protocols, and it has been investigated both alone and alongside GLP-1 receptor agonists in published metabolic research. Cagrilintide is not an approved medicine and remains investigational. Supplied strictly as a research compound for laboratory use.